A single pivotal adaptive trial in infants with proliferating hemangioma

Rationale, design challenges, experience and recommendations

Stephane Heritier, Caroline C. Morgan-Bouniol, Serigne N. Lo, Stephanie Gautier, Jean Jacques Voisard

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

4 Citations (Scopus)

Abstract

This chapter reflects on our experience when designing and analysing an adaptive confirmatory trial (previously referred to as a seamless Phase II/III trial) in infants with hemangioma over the 2009-2013 period. At the end of the first stage (Phase II) an interim analysis was conducted by an independent data monitoring committee allowing three possible adaptations: 1) selection of one or two active treatment regimens for further study in the second stage (Phase III); 2) sample size reestimation; 3) early stopping for futility. The trial design was defended before the FDA and the EMA prior to trial initiation in 2010, and the primary endpoint was analyzed in 2012. Marketing authorization for the pediatric drug Hemangeol (propranolol hydrochloride) was granted to the sponsor, Pierre Fabre Dermatologie, by the FDA (for orphan indication) in March 2014, and by the EMA in April 2014 under a different spelling (Hemangiol). Hemangeol is the first and only approved treatment for “proliferating infantile hemangioma requiring systemic therapy”. This single pivotal trial is one of the first adaptive confirmatory trials to be conducted successfully in the regulatory setting.

Original languageEnglish
Title of host publicationModern Adaptive Randomized Clinical Trials
Subtitle of host publicationStatistical and Practical Aspects
EditorsOleksandr Sverdlov
Place of PublicationBoca Raton FL USA
PublisherCRC Press
Pages453-482
Number of pages30
ISBN (Electronic)9781482239898
ISBN (Print)9781482239881
DOIs
Publication statusPublished - Jun 2015

Cite this

Heritier, S., Morgan-Bouniol, C. C., Lo, S. N., Gautier, S., & Voisard, J. J. (2015). A single pivotal adaptive trial in infants with proliferating hemangioma: Rationale, design challenges, experience and recommendations. In O. Sverdlov (Ed.), Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects (pp. 453-482). Boca Raton FL USA: CRC Press. https://doi.org/10.1201/b18640
Heritier, Stephane ; Morgan-Bouniol, Caroline C. ; Lo, Serigne N. ; Gautier, Stephanie ; Voisard, Jean Jacques. / A single pivotal adaptive trial in infants with proliferating hemangioma : Rationale, design challenges, experience and recommendations. Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects. editor / Oleksandr Sverdlov. Boca Raton FL USA : CRC Press, 2015. pp. 453-482
@inbook{9666b866879b4b45942a7e5fc366109f,
title = "A single pivotal adaptive trial in infants with proliferating hemangioma: Rationale, design challenges, experience and recommendations",
abstract = "This chapter reflects on our experience when designing and analysing an adaptive confirmatory trial (previously referred to as a seamless Phase II/III trial) in infants with hemangioma over the 2009-2013 period. At the end of the first stage (Phase II) an interim analysis was conducted by an independent data monitoring committee allowing three possible adaptations: 1) selection of one or two active treatment regimens for further study in the second stage (Phase III); 2) sample size reestimation; 3) early stopping for futility. The trial design was defended before the FDA and the EMA prior to trial initiation in 2010, and the primary endpoint was analyzed in 2012. Marketing authorization for the pediatric drug Hemangeol (propranolol hydrochloride) was granted to the sponsor, Pierre Fabre Dermatologie, by the FDA (for orphan indication) in March 2014, and by the EMA in April 2014 under a different spelling (Hemangiol). Hemangeol is the first and only approved treatment for “proliferating infantile hemangioma requiring systemic therapy”. This single pivotal trial is one of the first adaptive confirmatory trials to be conducted successfully in the regulatory setting.",
author = "Stephane Heritier and Morgan-Bouniol, {Caroline C.} and Lo, {Serigne N.} and Stephanie Gautier and Voisard, {Jean Jacques}",
year = "2015",
month = "6",
doi = "10.1201/b18640",
language = "English",
isbn = "9781482239881",
pages = "453--482",
editor = "Oleksandr Sverdlov",
booktitle = "Modern Adaptive Randomized Clinical Trials",
publisher = "CRC Press",
address = "Australia",

}

Heritier, S, Morgan-Bouniol, CC, Lo, SN, Gautier, S & Voisard, JJ 2015, A single pivotal adaptive trial in infants with proliferating hemangioma: Rationale, design challenges, experience and recommendations. in O Sverdlov (ed.), Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects. CRC Press, Boca Raton FL USA, pp. 453-482. https://doi.org/10.1201/b18640

A single pivotal adaptive trial in infants with proliferating hemangioma : Rationale, design challenges, experience and recommendations. / Heritier, Stephane; Morgan-Bouniol, Caroline C.; Lo, Serigne N.; Gautier, Stephanie; Voisard, Jean Jacques.

Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects. ed. / Oleksandr Sverdlov. Boca Raton FL USA : CRC Press, 2015. p. 453-482.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

TY - CHAP

T1 - A single pivotal adaptive trial in infants with proliferating hemangioma

T2 - Rationale, design challenges, experience and recommendations

AU - Heritier, Stephane

AU - Morgan-Bouniol, Caroline C.

AU - Lo, Serigne N.

AU - Gautier, Stephanie

AU - Voisard, Jean Jacques

PY - 2015/6

Y1 - 2015/6

N2 - This chapter reflects on our experience when designing and analysing an adaptive confirmatory trial (previously referred to as a seamless Phase II/III trial) in infants with hemangioma over the 2009-2013 period. At the end of the first stage (Phase II) an interim analysis was conducted by an independent data monitoring committee allowing three possible adaptations: 1) selection of one or two active treatment regimens for further study in the second stage (Phase III); 2) sample size reestimation; 3) early stopping for futility. The trial design was defended before the FDA and the EMA prior to trial initiation in 2010, and the primary endpoint was analyzed in 2012. Marketing authorization for the pediatric drug Hemangeol (propranolol hydrochloride) was granted to the sponsor, Pierre Fabre Dermatologie, by the FDA (for orphan indication) in March 2014, and by the EMA in April 2014 under a different spelling (Hemangiol). Hemangeol is the first and only approved treatment for “proliferating infantile hemangioma requiring systemic therapy”. This single pivotal trial is one of the first adaptive confirmatory trials to be conducted successfully in the regulatory setting.

AB - This chapter reflects on our experience when designing and analysing an adaptive confirmatory trial (previously referred to as a seamless Phase II/III trial) in infants with hemangioma over the 2009-2013 period. At the end of the first stage (Phase II) an interim analysis was conducted by an independent data monitoring committee allowing three possible adaptations: 1) selection of one or two active treatment regimens for further study in the second stage (Phase III); 2) sample size reestimation; 3) early stopping for futility. The trial design was defended before the FDA and the EMA prior to trial initiation in 2010, and the primary endpoint was analyzed in 2012. Marketing authorization for the pediatric drug Hemangeol (propranolol hydrochloride) was granted to the sponsor, Pierre Fabre Dermatologie, by the FDA (for orphan indication) in March 2014, and by the EMA in April 2014 under a different spelling (Hemangiol). Hemangeol is the first and only approved treatment for “proliferating infantile hemangioma requiring systemic therapy”. This single pivotal trial is one of the first adaptive confirmatory trials to be conducted successfully in the regulatory setting.

UR - http://www.scopus.com/inward/record.url?scp=85009447111&partnerID=8YFLogxK

U2 - 10.1201/b18640

DO - 10.1201/b18640

M3 - Chapter (Book)

SN - 9781482239881

SP - 453

EP - 482

BT - Modern Adaptive Randomized Clinical Trials

A2 - Sverdlov, Oleksandr

PB - CRC Press

CY - Boca Raton FL USA

ER -

Heritier S, Morgan-Bouniol CC, Lo SN, Gautier S, Voisard JJ. A single pivotal adaptive trial in infants with proliferating hemangioma: Rationale, design challenges, experience and recommendations. In Sverdlov O, editor, Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects. Boca Raton FL USA: CRC Press. 2015. p. 453-482 https://doi.org/10.1201/b18640